MedTrace Logo

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

NCT02751918 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2019-11-22

No results posted yet for this study

Summary

Anetumab ravtansine is developed for the treatment of patients with recurrent platinum-resistant ovarian cancer. The purpose of the proposed trial is to identify the maximum tolerated dose of anetumab ravtansine that could be safely combined with pegylated liposomal doxorubicin in this indication.

Conditions

  • Ovarian Neoplasms

Interventions

DRUG

Anetumab ravtansine (BAY94-9343)

Anetumab ravtansine will be administered on Day 1 of every 21-day treatment cycle.

DRUG

Pegylated Liposomal Doxorubicin

Pegylated liposomal doxoribicin will be administered on Day 1 of every 21-day treatment cycle.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-08
Primary Completion
2019-08-23
Completion
2019-10-31
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Moldova
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02751918 on ClinicalTrials.gov